|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2004-8-5
|
|
pubmed:abstractText |
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:BrancoLuisL,
pubmed-author:CoreyLawrenceL,
pubmed-author:DeVincenzoJohn PJP,
pubmed-author:EnglundJanet AJA,
pubmed-author:HallCaroline BCB,
pubmed-author:JantauschBarbara ABA,
pubmed-author:JohnsonSydS,
pubmed-author:KahnJeffrey SJS,
pubmed-author:KimberlinDavid WDW,
pubmed-author:Palmer-HillFrances JFJ,
pubmed-author:PatelNita KNK,
pubmed-author:PiazzaFranco MFM,
pubmed-author:RodriguezWilliam JWJ,
pubmed-author:SánchezPablo JPJ,
pubmed-author:SuzichJoAnn AJA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
190
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
975-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15295704-Antibodies, Monoclonal,
pubmed-meshheading:15295704-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15295704-Antiviral Agents,
pubmed-meshheading:15295704-Cell Line,
pubmed-meshheading:15295704-Drug Resistance, Viral,
pubmed-meshheading:15295704-Fluorescent Antibody Technique,
pubmed-meshheading:15295704-Hospitalization,
pubmed-meshheading:15295704-Humans,
pubmed-meshheading:15295704-Infant,
pubmed-meshheading:15295704-Microbial Sensitivity Tests,
pubmed-meshheading:15295704-Mutation,
pubmed-meshheading:15295704-Neutralization Tests,
pubmed-meshheading:15295704-Respiratory Syncytial Virus, Human,
pubmed-meshheading:15295704-Respiratory Syncytial Virus Infections
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
|
|
pubmed:affiliation |
University of Tennessee, LeBonheur Children's Medical Center, Memphis 38103, USA. jdevincenzo@utmem.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
